Hepatology papers
Pofolia’s corpus holds 77 papers from Hepatology (2012–2026), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020, 7,315 citations).
- The 20 papers listed have 56,636 citations between them.
- 17 of the 19 with a known journal quartile appeared in a Q1 journal.
- 15 have a free full text (open access).
- Most frequent journals: Hepatology, New England Journal of Medicine, Journal of Clinical Oncology.
- Published between 2012 and 2023.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 457.40 · 7,315 citations · Open access
Combining atezolizumab and bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma compared to sorafenib.
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Case Reports in Gastroenterology · 2017 · Q4 · FWCI 315.25 · 5,377 citations · Open access
This case report highlights the rare occurrence of spontaneous hepatocellular carcinoma (HCC) rupture, which presents an emergency requiring difficult treatment decisions.
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Digestive Diseases · 2014 · Q2 · FWCI 247.12 · 4,864 citations · Open access
Novel in vitro cell culture models have been crucial for identifying and profiling therapeutic strategies against Hepatitis C virus (HCV), revealing host factors essential for viral propagation that are now emerging as antiviral targets.
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Hepatology · 2018 · Q1 · SJR 7.00 · FWCI 203.30 · 4,627 citations · Open access
This document provides updated practice guidance for the diagnosis, staging, and management of Hepatocellular Carcinoma (HCC) from the American Association for the Study of Liver Diseases (AASLD). It reflects the latest evidence and recommendations for clinicians.
AASLD guidelines for the treatment of hepatocellular carcinoma
Hepatology · 2017 · Q1 · SJR 7.00 · FWCI 173.47 · 4,178 citations · Open access
The American Association for the Study of Liver Diseases (AASLD) has released updated guidelines for HCC treatment in adults with cirrhosis, adhering to Institute of Medicine standards and employing the GRADE approach.
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Journal of Clinical Oncology · 2014 · Q1 · SJR 4.00 · FWCI 21.75 · 2,783 citations · Open access
A new Albumin-Bilirubin (ALBI) grade, based solely on serum bilirubin and albumin levels, accurately assesses liver function in hepatocellular carcinoma (HCC) patients and performs as well as or better than the conventional Child-Pugh (C-P) grade.
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Hepatology · 2012 · Q1 · SJR 7.00 · FWCI 93.63 · 2,521 citations · Open access
Global prevalence of antibodies to Hepatitis C Virus (HCV) increased from 2.3% to 2.8% between 1990 and 2005, with the number of infected individuals rising from over 122 million to over 185 million.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 123.63 · 2,348 citations · Open access
In previously treated patients with advanced liver cancer, cabozantinib significantly improved overall survival by 2.2 months and progression-free survival by 3.3 months compared to placebo.
Treatment of HCV Infection by Targeting MicroRNA
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 134.54 · 2,193 citations · Open access
Miravirsen, an antisense oligonucleotide targeting microRNA-122, demonstrated a dose-dependent and prolonged reduction in HCV RNA levels in patients with chronic genotype 1 infection.
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Hepatology International · 2017 · Q1 · SJR 1.00 · FWCI 84.35 · 2,186 citations · Open access
Updated clinical practice guidelines for hepatocellular carcinoma (HCC) management in the Asia-Pacific region have been released, offering evidence-based recommendations tailored for diverse medical environments.
Portal hypertensive bleeding in cirrhosis
Hepatology · 2016 · Q1 · SJR 7.00 · FWCI 70.58 · 2,107 citations
This guidance offers a data-supported approach to stratifying risk, diagnosing, and managing patients with cirrhosis and portal hypertension, emphasizing individualized care based on disease stage.
Global burden of primary liver cancer in 2020 and predictions to 2040
Journal of Hepatology · 2022 · Q1 · SJR 13.00 · FWCI 214.86 · 2,094 citations
In 2020, an estimated 905,700 people were diagnosed with and 830,200 died from liver cancer globally, with rates highest in Eastern Asia, Northern Africa, and South-Eastern Asia.
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
Hepatology · 2014 · Q1 · SJR 7.00 · FWCI 43.77 · 2,057 citations · Open access
This practice guideline provides a data-supported approach to the diagnosis, treatment, and prevention of hepatic encephalopathy (HE) in chronic liver disease, based on a formal review of global literature and expert experience.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Journal of Clinical Oncology · 2019 · Q1 · SJR 4.00 · FWCI 120.88 · 1,824 citations
In advanced liver cancer patients previously treated with sorafenib, pembrolizumab plus best supportive care (BSC) showed a trend towards improved overall survival (OS) and progression-free survival (PFS) compared to placebo plus BSC, but did not meet statistical significance thresholds.
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 159.49 · 1,784 citations
A 12-week sofosbuvir-based regimen achieved a 90% sustained virologic response rate in previously untreated patients with Hepatitis C genotypes 1, 4, 5, or 6. In a separate trial, sofosbuvir plus ribavirin was non-inferior to standard therapy for genotypes 2 or 3, with fewer adverse events.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Hepatology · 2023 · Q1 · SJR 7.00 · FWCI 266.33 · 1,745 citations
This document provides updated practice guidance for the prevention, diagnosis, and treatment of hepatocellular carcinoma (HCC). It synthesizes current evidence and expert consensus to inform clinical decision-making.
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
The Lancet. Gastroenterology & hepatology · 2020 · FWCI 119.07 · 1,717 citations · Open access
Globally, cirrhosis deaths rose 48% from 1990 to 2017, reaching 1.32 million, despite a decrease in age-standardized death rates. Non-alcoholic steatohepatitis (NASH) emerged as a rapidly growing cause, with its prevalence increasing significantly.
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 144.45 · 1,709 citations · Open access
A 12-week treatment of ledipasvir-sofosbuvir achieved a 99% sustained virologic response rate in previously untreated patients with Hepatitis C Virus (HCV) genotype 1 infection.
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Cell · 2014 · Q1 · SJR 24.00 · FWCI 31.13 · 1,625 citations · Open access
Researchers have developed a method to expand adult human liver stem cells long-term in culture, maintaining their genome stability and ability to differentiate into functional liver cells.
Global distribution and prevalence of hepatitis C virus genotypes
Hepatology · 2014 · Q1 · SJR 7.00 · FWCI 82.46 · 1,582 citations · Open access
Hepatitis C virus (HCV) genotype 1 is the most prevalent globally, accounting for 46.2% of cases (83.4 million), with genotype 3 being the second most common (30.1%).
Recently added
Lactococcus lactis and Aspergillus fumigatus co-infection in cirrhotic patients: a case study and literature review
BMC Infectious Diseases · 2026 · Q1
This paper reports the first documented case of spinal infection caused by a co-infection of Lactococcus lactis and Aspergillus fumigatus in a patient with hepatitis C-related cirrhosis.
Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study
European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Q1 · SJR 2.00
Direct Y-90 infusion via the inferior phrenic artery (IPA) achieved superior tumor response (82.3% at 3 months) compared to IPA embolization (69.7%) in hepatocellular carcinoma (HCC) patients, particularly when tumor volume was ≥ 20 mL and non-target vessels were manageable.
Development and validation of a nomogram for predicting 28-day mortality in critically ill liver cirrhotic patients with coagulopathy
BMC Gastroenterology · 2026 · Q2
A new nomogram accurately predicts 28-day mortality in critically ill cirrhotic patients with coagulopathy, outperforming existing scores like SOFA and MELD3.0.
TNFSF14 Regulates Th9 Differentiation and Hepatobiliary Inflammation in Primary Biliary Cholangitis
Inflammation · 2026 · Q1 · SJR 1.00
TNFSF14 expression in CD4+ T cells drives Th9 differentiation and promotes hepatobiliary inflammation in primary biliary cholangitis (PBC) by activating NF-κB signaling in biliary epithelial cells (BECs), leading to increased IL-34 production and macrophage accumulation.
Driver gene-based prognostic model benchmarked against machine learning survival models is associated with a CAF–TGFβ–EMT-like phenotype in hepatocellular carcinoma
npj Precision Oncology · 2026 · Q1 · SJR 3.00
A 13-gene driver gene prognostic model (DGPM-HCC) achieved a mean C-index of 0.761, outperforming a continuous Cox model by 0.125 (P = 9.57 × 10−5) in hepatocellular carcinoma (HCC) prognosis, and was associated with a CAF–TGFβ–EMT-like tumor microenvironment.
Characteristics of ascitic fluid and diagnosis of bacterial peritonitis in malignant ascites: An observational study
Journal of Hospital Medicine · 2026 · Q1
Ascitic fluid polymorphonuclear (PMN) percentage ≥ 63% (90.8% specificity) or PMN cell count > 1318 cells/mm³ (93.0% specificity) are proposed as diagnostic thresholds for bacterial peritonitis in malignant ascites, outperforming the standard SBP threshold of PMN count ≥ 250 cells/mm³.
Multi-organelle signatures map cell-state diversity and metabolic adaptation in tissues
Science · 2026 · Q1 · SJR 10.00
Spatial Organellomics (sOrganellomics) uses imaging and machine learning to map cell states based on multi-organelle signatures, revealing intermixed hepatocyte communities within liver zones and linking fasting-induced organelle remodeling to altered mitochondrial membrane potential.
Impaired Lung Function in Liver Transplant Recipients Compared With the General Population: A Nationwide Matched Cohort Study
Transplantation · 2026 · Q1 · SJR 1.00
Liver transplant recipients show significantly higher rates of airflow limitation (10.7% vs 7.1%) and preserved ratio impaired spirometry (PRISm) (23.8% vs 11.8%) compared to the general population.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 10 | 376 |
| Hepatology | Q1 | 7.00 | 424 | 9 | 17 |
| Journal of Clinical Oncology | Q1 | 4.00 | 666 | 4 | 38 |
| Radiology | Q1 | 4.00 | 357 | 2 | 14 |
| American Journal of Gastroenterology | Q1 | 2.00 | 307 | 2 | 18 |
| Cancers | Q1 | 1.00 | 182 | 2 | 10 |
| Medicina (Lithuania) | Q2 | — | 86 | 2 | 9 |
| Cell | Q1 | 24.00 | 956 | 1 | 9 |
Every journal in Hepatology (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app